AEGiS-Glasgow [KL3] Where are we going with HIV prevention, treatment and care at a global level?

Eighth International Congress on Drug Therapy in HIV Infection

Glasgow, UK - 12-16 November 2006

[KL3] Where are we going with HIV prevention, treatment and care at a global level?

Int Cong Drug Therapy HIV 2006 Nov 12-16;8:Abstract No. KL3

Kevin M De Cock
World Health Organization, Geneva, Switzerland

PURPOSE OF THE STUDY: 2006 marks the 25th anniversary of the first description of AIDS and the 10th anniversary of the recognition of the effectiveness of combination antiretroviral therapy (ART). Despite success in several spheres, including substantially increased resources for the global response (approximately 8.3 billion US dollars in 2005) and increased access to therapy (approximately 1.65 million people on ART in low and middle income countries by end-June 2006), the epidemic is far from controlled. By end-2005, 38.6 million persons were estimated to be living with HIV worldwide, with 4.1 million new infections and 2.8 million deaths occurring during that year alone. A commitment has been made by the world community to work towards universal access to HIV prevention, treatment and care. To approach that goal will require a greatly strengthened health sector, increased knowledge of HIV serostatus, reinvigoration of prevention, continued expansion of treatment access, and investment in appropriate strategic information. As increased numbers of people access treatment, resource requirements for HIV/AIDS will also increase, highlighting the need for effective prevention and innovative financing methods. How HIV/AIDS will fare in global prioritization in the coming decade will depend on epidemiologic trends as well as programmatic performance, in a complex world with other emerging threats.

Plenary Session: Keynote Lectures (Past, Present and Future)

2006-11-12
KL3

Copyright © 2006 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.